Financial Performance - The company's operating revenue for the first half of 2023 was ¥2,115,775,975.35, representing a 7.49% increase compared to ¥1,968,361,705.33 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was ¥51,153,193.68, a 33.85% increase from ¥38,217,373.51 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was ¥49,490,125.29, which is a 51.65% increase compared to ¥32,634,664.86 in the same period last year[20]. - The net cash flow from operating activities was ¥97,507,945.74, a significant improvement of 258.95% from -¥61,343,605.85 in the previous year[20]. - Basic earnings per share increased to ¥0.1531, up 33.83% from ¥0.1144 in the same period last year[20]. - Total revenue for the reporting period reached ¥2,115,775,975.35, representing a year-on-year increase of 7.49% from ¥1,968,361,705.33[67]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,041,928,119.67, a decrease of 5.79% from ¥3,228,804,787.20 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company were ¥1,953,413,966.49, reflecting a 1.61% increase from ¥1,922,470,592.26 at the end of the previous year[20]. - Cash and cash equivalents increased to ¥624,742,784.73, representing 20.54% of total assets, up from 14.04% last year[71]. - Inventory stood at ¥718,939,466.58, accounting for 23.63% of total assets, a slight increase from 22.42%[72]. Revenue Segmentation - The pharmaceutical industry contributed ¥374,808,949.17, accounting for 17.71% of total revenue, with a year-on-year growth of 17.87%[67]. - The pharmaceutical commercial sector generated ¥1,740,967,026.18, which is 82.29% of total revenue, showing a growth of 5.49% compared to the previous year[67]. - Domestic revenue was ¥2,105,042,737.00, making up 99.49% of total revenue, with a year-on-year increase of 7.51%[67]. Market Position and Strategy - The company ranked 49th in the "Top 100 Pharmaceutical Commercial Enterprises" list for 2022-2023, indicating its strong market position[37]. - The company is focusing on optimizing customer structure and expanding retail terminal networks to enhance operational quality and profitability[36]. - The company is positioned to benefit from the national policy promoting high-quality development in the pharmaceutical distribution industry, aiming for the top 100 wholesale enterprises to account for over 98% of the market by the end of the 14th Five-Year Plan[30]. Retail and Online Sales - The company achieved a retail revenue of 599.83 million yuan in the first half of 2023, with a year-on-year growth of 10.27%[37]. - The net profit for the retail segment reached 18.75 million yuan, reflecting a significant increase of 53.1% year-on-year[37]. - Online sales reached a total of 2,045.85 million RMB in the first half of 2023, representing a year-on-year growth of 58.81%[46]. Research and Development - Research and development investment increased by 5.13% to approximately ¥20.35 million, up from ¥19.35 million in the previous year[64]. - The company is advancing the development of new products, including the consistent evaluation of the generic drug for injection chlorpromazine and the orderly progress of the development of losartan and flurbiprofen gel patches[55]. - The company has obtained a total of 27 domestic invention patents and 4 foreign invention patents, reflecting its commitment to innovation and technology development[60]. Environmental and Social Responsibility - The company is classified as a key pollutant discharge unit and strictly adheres to various environmental protection laws and standards[97]. - The company has conducted nearly 200 community health events as part of its social responsibility initiatives in the first half of the year[109]. - Zhenyuan Pharmaceutical has actively engaged in community health services, establishing 20 community health service stations, leading the city in quantity[108]. Corporate Governance - The company did not undergo any bankruptcy restructuring during the reporting period[118]. - There were no significant litigation or arbitration matters during the reporting period[118]. - The company reported no major related party transactions during the reporting period[118]. Shareholder Information - The total number of shares remained at 334,123,286, with no changes in the total share count[133]. - The largest shareholder, Shaoxing Zhenyuan Health Industry Group Co., Ltd., holds 24.93% of shares, totaling 83,300,474 shares[135]. - The company has a registered capital of 334,123,286.00 RMB and a total of 334,123,286 shares outstanding[146].

浙江震元股份有限公司十届十三次董事会决议公告 证券代码：000705 证券简称：浙江震元 公告编号：2023-036 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江震元股份有限公司十届十三次董事会会议通知于 2023 年 8 月 7 日以电话形式通知，于 2023 年 8 月 17 日以通讯形式召开。会议应出 具表决意见董事 9 人，在规定时间内收到审议意见函 9 份。本次董事 会会议的召开符合有关法律、行政法规、部门规章、规范性文件和公 司章程的有关规定。 二、董事会会议审议情况 1、9 票同意，0 票反对，0 票弃权，审议通过《关于向银行申请授 信的议案》；同意以信用方式向中国工商银行绍兴分行、中国银行绍兴 市分行、浙商银行绍兴越城支行、杭州银行绍兴分行、绍兴银行、浙 江绍兴瑞丰农村商业银行股份有限公司镜湖支行等 6 家银行申请本 金金额不超过人民币 10 亿元的综合授信额度，授信期限自董事会批准 同意日起一年；综合授信额度以银行实际审批的授信额度为准，具体 融资金额视公司实际资金需求和银行审批情况确定；授信期限内，授 信额度 ...

非经营性资金占用及其他关联资金往来情况汇总表 2023年6月 主管会计工作的负责人:柴军 会计机构负责人:丁佩娟 | 编制单位:班,震元股份有限公司 | | | | | | | | | | 单位:人民币万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性次会 | 资金占用方名称 | 占用方与上市公司的关 联关系 | 上市公司核算的 会计科目 | 2023年期初 占用资金余额 | 累计发生金额 (不含利息) | 2023年1-6月占用 2023年1-6月占用资 金的利息 (如有) | 2023年1-6月偿还 累计发生金额 | 2023年6月期末 占用资金余额 | 占用形成原因 | 占用性质 | | 其附属企业 | | | | | | | | | | 非经营性占用 | | | | | | | | | | | | 非经营性占用 | | 三 计 | | - | | | | | | | | | | 前控股股东,实际控制人及其附属企业 | | | | | | | | | | 非经营性占用 | | | | | | | ...

浙江震元股份有限公司十届十三次董事会 浙江震元股份有限公司独立董事就相关事项的独立意见 作为浙江震元股份有限公司独立董事，我们根据《公司章程》、《公 司独立董事制度》等规定，认真审慎地核查公司相关资料，现就 2023 年半年度相关事项发表独立意见如下： 一、控股股东及其他关联方非经营性占用公司资金 本报告期内，公司不存在控股股东及其他关联方占用公司资金的情 况。 浙江震元股份有限公司独立董事： 邢小玲 程幸福 袁建伟 2023 年 8 月 17 日 二、对外担保 截止 2023 年 6 月 30 日，公司对外担保余额为零。公司没有对外担 保，亦无逾期担保。 三、关于向银行申请授信 公司生产经营情况正常，具有良好的盈利能力及偿债能力。公司以 信用方式向银行申请本金金额不超过人民币 10 亿元的授信额度，有利 于促进公司现有业务的持续稳定发展和推进医药健康产业生态链的建 设布局，将对公司整体实力和盈利能力的提升产生积极意义。公司召 开董事会审议通过了《关于向银行申请授信的议案》，决策程序合法 合规，不存在损害股东利益的行为，我们同意该议案。 ...

关于完成工商变更登记的公告 证券代码：000705 证券简称：浙江震元 公告编号：2023-035 浙江震元股份有限公司 成立日期：1993 年 4 月 2 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 日前，浙江震元股份有限公司 (以下简称"公司") 完成了经营 范围的变更登记手续，并取得浙江省市场监督管理局换发的《营业执 照》，具体内容如下： 名称：浙江震元股份有限公司 统一社会信用代码：91330000145919552E 类型：其他股份有限公司（上市） 住所：浙江省绍兴市稽山街道延安东路 558 号 法定代表人：吴海明 注册资金：叁亿叁仟肆佰壹拾贰万叁仟贰佰捌拾陆元 2 业执照依法自主开展经营活动)。 经营范围：许可项目：药品批发；食品销售；药品生产；第三类 医疗器械经营；消毒器械销售；第二类增值电信业务；互联网信息服 务；兽药经营；中药饮片代煎服务(依法须经批准的项目，经相关部门 批准后方可开展经营活动，具体经营项目以审批结果为准)。一般项目： 特殊医学用途配方食品销售；食品销售（仅销售预包装食品）；婴幼儿 1 配方乳粉及其他婴幼儿配方食品销售 ...

1 证券代码：000705 证券简称：浙江震元 浙江震元股份有限公司投资者关系活动记录表 编号：2023-002 | 投资者关系活 | 分析师会议 □特定对象调研 □ | | | | | | --- | --- | --- | --- | --- | --- | | 动类别 | □ 媒体采访 √ 业绩说明会 | | | | | | | □ 新闻发布会 □ 路演活动 | | | | | | | □ 现场参观 | | | | | | | 其他 （请文字说明其他活动内容） □ | | | | | | 参与单位名称 | 投资者网上提问 | | | | | | 及人员姓名 | | | | | | | 时间 | 年 2023 (周五) | 5 | 月 | 12 | 日 | | 地点 | 公 司 通 过 全 景 网 " 投 资 者 关 系 互 动 平 台 " | | | | | | | （https://ir.p5w.net）采用网络远程的方式召开业绩 | | | | | | | 说明会 | | | | | | 上市公司接待 | 1、董事长吴海明 | | | | | | 人员姓名 | 2、副董事长、总经理柴军 | | | ...

证券代码：000705 证券简称：浙江震元 公告编号：2023-019 浙江震元股份有限公司 关于参加浙江辖区上市公司 2023 年投资者网上集体接待日 活动暨 2022 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，浙江震元股份有限公司（以 下简称"公司"）将参加由浙江证监局、浙江省上市公司协会与深圳 市全景网络有限公司联合举办的"2023 年浙江辖区上市公司投资者 集体接待日活动" 暨公司 2022 年度业绩说明会，现将相关事项公告 如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演" 网站（https://rs.p5w.net），或关注微信公众号：全景财经，或下 载全景路演APP,参与本次互动交流，活动时间为2023年5月12日（周 五）15:00-17:00。届时公司董事长吴海明先生；副董事长、总经理 柴军先生（代行财务总监）；董事会秘书周黔莉女士将在线，就公司 2022年度业绩、公司治理、发展战略、 经营状况等投资者关心的问 题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 为 ...

证券代码：000705 证券简称：浙江震元 公告编号：2023-019 浙江震元股份有限公司 （问题征集专题页面二维码） 特此公告。 浙江震元股份有限公司董事会 2023 年 5 月 8 日 关于参加浙江辖区上市公司 2023 年投资者网上集体接待日 活动暨 2022 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，浙江震元股份有限公司（以 下简称"公司"）将参加由浙江证监局、浙江省上市公司协会与深圳 市全景网络有限公司联合举办的"2023 年浙江辖区上市公司投资者 集体接待日活动" 暨公司 2022 年度业绩说明会，现将相关事项公告 如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演" 网站（https://rs.p5w.net），或关注微信公众号：全景财经，或下 载全景路演APP,参与本次互动交流，活动时间为2023年5月12日（周 五）15:00-17:00。届时公司董事长吴海明先生；副董事长、总经理 柴军先生（代行财务总监）；董事会秘书周黔莉女士将在线，就公司 2022年度业绩、公司治 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 1,098,106,955.60, representing a 13.88% increase compared to CNY 964,264,259.83 in the same period last year[8]. - Net profit attributable to shareholders was CNY 18,564,267.15, up 22.32% from CNY 15,176,300.98 year-on-year[8]. - The company reported a significant increase in net profit after deducting non-recurring gains and losses, which reached CNY 18,141,480.93, a 43.39% increase from CNY 12,651,652.58 in the previous year[8]. - Operating profit for Q1 2023 was RMB 26,499,583.72, up 37.9% from RMB 19,207,955.22 year-on-year[22]. - Total comprehensive income for Q1 2023 was RMB 18,878,980.49, compared to RMB 9,921,713.67 in Q1 2022[22]. Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to CNY 4,328,543.90, a 102.96% increase from a negative cash flow of CNY -146,188,505.11 in the previous year[8]. - The company reported a net cash flow from operating activities of RMB 4,328,543.90, a significant improvement from a negative RMB 146,188,505.11 in the previous year[24]. - Cash and cash equivalents were RMB 418,758,680.05, compared to RMB 453,484,094.17 at the beginning of the quarter[21]. - Cash and cash equivalents at the end of Q1 2023 totaled RMB 398,480,777.79, compared to RMB 239,534,691.49 at the end of Q1 2022[24]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,180,750,392.19, a decrease of 1.49% from CNY 3,228,804,787.20 at the end of the previous year[8]. - Current assets totaled RMB 2,066,776,798.13, down from RMB 2,109,682,646.88 at the start of the quarter[21]. - Total liabilities were RMB 1,215,943,912.23, down from RMB 1,282,876,202.82[21]. - Current liabilities totaled RMB 1,030,132,070.51, a decrease from RMB 1,094,951,501.72[21]. Shareholder Equity - The net assets attributable to shareholders increased to CNY 1,940,045,142.50, marking a 0.91% rise from CNY 1,922,470,592.26 at the end of the last year[8]. - The company's equity attributable to shareholders was RMB 1,940,045,142.50, slightly up from RMB 1,922,470,592.26[21]. - The company reported a net profit of RMB 838,807,368.57 in retained earnings, compared to RMB 820,243,101.42 at the beginning of the quarter[21]. Earnings Per Share - The basic earnings per share rose to CNY 0.0556, reflecting a 22.47% increase compared to CNY 0.0454 in the same period last year[8]. - Basic and diluted earnings per share for Q1 2023 were both RMB 0.0556, an increase from RMB 0.0454 in the same period last year[22]. Other Financial Metrics - The weighted average return on equity improved to 0.96%, up from 0.82% in the previous year, an increase of 0.14 percentage points[8]. - Research and development expenses for Q1 2023 were RMB 8,840,762.38, slightly up from RMB 8,045,330.27 in the same period last year[22]. - The company experienced a decrease in other comprehensive income, with a net amount of RMB -988,632.00 compared to RMB -5,746,211.00 in Q1 2022[22]. - The report for the first quarter of 2023 was not audited[20]. Investment Income - Investment income dropped significantly by 97.52% to CNY 49,817.82 compared to CNY 2,009,102.68 in the previous year, primarily due to the expiration of financial products[12]. Contract Liabilities - The company experienced a 60.49% decrease in contract liabilities, down to CNY 11,895,987.12 from CNY 30,111,854.29[12].

浙江震元股份有限公司2022年年度报告 浙江震元股份有限公司 2022 年年度报告 ...